Lymphoma Clinical Trials in Pennsylvania

Showing 541-560 of 564 trials

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

NCT00053105

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase I trial to study the effect of combination chemotherapy on the body when treating patients who have relapsed or refractory aggressive non-Hodgkin's lymphoma.

Lymphoma

TheradexStarted Feb 2002

Tucson, Arizona, United States • Springdale, Arkansas, United States • Los Angeles, California, United States +4 more locations

TERMINATEDPhase 195 miles

Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia

NCT00105313

For primary objectives, we will determine the MTD and examine clinical responses and immune cell populations to determine an OBD, and describe the safety and tolerability of MEDI-507. For the secondary objectives we will look at the antitumor activity of MEDI 507, PK, serum concentrations, and immunogenicity of MEDI-507, as well as time courses of depletion and recovery of CD2 positive and total T-Cell populations.

LymphomaLeukemiaCancer

MedImmune LLC80 participantsStarted Feb 2005

Los Angeles, California, United States • New Haven, Connecticut, United States • Washington D.C., District of Columbia, United States +8 more locations

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia

Lymphoma Trials in Other Cities

Topotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia, Lymphoma, or Solid Tumors

Forodesine in the Treatment of Cutaneous T-Cell Lymphoma

VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

Study of Untreated or Transformed Follicular Non-Hodgkin's Lymphoma With Fission-Derived Iodine I 131 Tositumomab

Pegylated Liposomal Doxorubicin Containing Chemotherapy in the Treatment of Older Non-Hodgkin's Lymphoma Patients

BAY 59-8862 in Treating Patients With Refractory Non-Hodgkin's Lymphoma

A Study of ONTAK in Patients With Relapsed or Refractory, B-Cell Non Hodgkin's Lymphoma

Bone Marrow Transplantation in Treating Patients With Leukemia, Myelodysplasia, or Lymphoblastic Lymphoma

Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's Lymphoma

DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas

A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies

Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Various Refractory Malignancies

Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin's Lymphoma

Bryostatin 1 and High Dose Cytarabine in Treating Patients With Refractory or Relapsed Leukemia or Lymphoma

Personalized Active Immunotherapy (Vaccine Therapy) and Sargramostim Given After Standard of Care Treatment With Rituximab and Chemotherapy for Initial Treatment With Lymphoma

Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma

Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects With Refractory Lymphoma

Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients

Other Conditions in Pennsylvania